Statins and the Lipid Management Debate Beyond Just LDL

Statins work by inhibiting HMG-CoA reductase, an enzyme central to cholesterol synthesis in the liver, and they remain among the most extensively studied drugs in modern medicine, with decades of large randomized trials demonstrating reduced cardiovascular events in various risk populations. Despite this deep evidence base, decisions about who should start statin therapy have become more nuanced than simply looking at a single LDL cholesterol number.

Modern cardiovascular risk assessment increasingly incorporates multiple data points beyond LDL alone, including ApoB, coronary artery calcium scoring, family history, and inflammatory markers like hs-CRP, to build a fuller individual risk picture. This shift reflects a broader recognition in preventive cardiology that cardiovascular risk is genuinely multifactorial, and that treatment decisions benefit from looking at the whole picture rather than any single lab value in isolation.

Why this matters for tracking: understanding that modern cardiovascular risk assessment goes well beyond a single LDL number helps make sense of why two people with similar cholesterol levels might receive very different treatment recommendations.